Literature DB >> 21742829

Population effectiveness, not efficacy, should decide who gets vaccinated against human papillomavirus via publicly funded programs.

Philip E Castle, Fang-Hui Zhao.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21742829     DOI： 10.1093/infdis/jir287

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  6 in total

1.  Declines in Anogenital Warts Among Age Groups Most Likely to Be Impacted by Human Papillomavirus Vaccination, United States, 2006-2014.

Authors:  Elaine W Flagg; Elizabeth A Torrone
Journal:  Am J Public Health       Date:  2017-11-21       Impact factor: 9.308

2.  Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination.

Authors:  Elaine W Flagg; Robert Schwartz; Hillard Weinstock
Journal:  Am J Public Health       Date:  2013-06-13       Impact factor: 9.308

Review 3.  Modeling preventative strategies against human papillomavirus-related disease in developed countries.

Authors:  Karen Canfell; Harrell Chesson; Shalini L Kulasingam; Johannes Berkhof; Mireia Diaz; Jane J Kim
Journal:  Vaccine       Date:  2012-11-20       Impact factor: 3.641

Review 4.  HPV vaccine acceptability among men: a systematic review and meta-analysis.

Authors:  Peter A Newman; Carmen H Logie; Nick Doukas; Kenta Asakura
Journal:  Sex Transm Infect       Date:  2013-07-04       Impact factor: 3.519

5.  Human Papillomavirus awareness and vaccine acceptability among men who have sex with men from mainland China.

Authors:  Xiangwei Li; Xuefang Cao; Zhen Li; Yu Yang; Mufei Li; Boxuan Feng; Henan Xin; Haoran Zhang; Lei Gao
Journal:  Sci Rep       Date:  2019-06-19       Impact factor: 4.379

6.  Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study.

Authors:  Amy Leval; Eva Herweijer; Alexander Ploner; Sandra Eloranta; Julia Fridman Simard; Joakim Dillner; Cecilia Young; Eva Netterlid; Pär Sparén; Lisen Arnheim-Dahlström
Journal:  J Natl Cancer Inst       Date:  2013-03-13       Impact factor: 13.506
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.